George Makavos1, Ignatios Ikonomidis2, Ioanna Andreadou3, Maria Varoudi1, Irini Kapniari4, Eleni Loukeri3, Kostas Theodoropoulos4, George Pavlidis1, Helen Triantafyllidi1, John Thymis1, John Parissis1, Maria Tsoumani3, Pinelopi Rafouli-Stergiou1, Pelagia Katsimbri5, Evangelia Papadavid4. 1. Second Department of Cardiology, National and Kapodistrian University of Athens Medical School, Attikon Hospital, Athens, Greece. 2. Second Department of Cardiology, National and Kapodistrian University of Athens Medical School, Attikon Hospital, Athens, Greece. Electronic address: ignoik@gmail.com. 3. Department of Pharmaceutical Chemistry, National and Kapodistrian University of Athens School of Pharmacy, Athens, Greece. 4. Second Department of Dermatology and Venereology, National and Kapodistrian University of Athens Medical School, Attikon Hospital, Athens, Greece. 5. Rheumatology and Clinical Immunology Unit, Fourth Department of Internal Medicine, National and Kapodistrian University of Athens Medical School, Attikon Hospital, Athens, Greece.
Abstract
BACKGROUND: Interleukin (IL)-17A activity is implicated in psoriasis. We investigated the effects of IL-17A inhibition on vascular and left ventricular (LV) function in patients with psoriasis. METHODS: A total of 150 patients with psoriasis received either an anti-IL-17A agent (secukinumab, n = 50), cyclosporine (n = 50), or methotrexate treatment (n = 50). At baseline and after 4 and 12 months of treatment, we measured (1) LV global longitudinal strain (GLS), GLS rate (GLSR), GLSR at early diastole, LV twisting, and untwisting; (2) coronary flow reserve (CFR); (3) pulse wave velocity (PWV); and (4) malondialdehyde and protein carbonyl as markers of oxidative stress. RESULTS: Compared with cyclosporine and methotrexate, anti-IL-17A treatment resulted in a greater increase in GLS at 4 and 12 months after treatment (10% and 14% with anti-IL-17A vs 2% and 2% with cyclosporine vs 4% and 4% with methotrexate, respectively), GLSR, GLSR at early diastole (45% and 41% vs 5% and 4% vs 7% and 9%, respectively), and LV twisting (32% and 28% vs 6% and 8% vs 7% and 6%, respectively) (P < 0.05). Anti-IL-17A treatment resulted in greater improvement of CFR and PWV than cyclosporine or methotrexate (P < 0.05). PWV increased after cyclosporine treatment (+11% at 4 and +14% and 12 months) (P < 0.05). Markers of oxidative stress were reduced only after anti-IL-17A treatment (P < 0.05). Changes of myocardial deformation markers and CFR after anti-IL-17A treatment correlated with a concomitant reduction of oxidative stress. CONCLUSIONS: In psoriasis, inhibition of IL-17A results in a greater improvement of vascular and myocardial function compared with cyclosporine or methotrexate treatment, indicating a beneficial effect on overall cardiovascular function.
BACKGROUND: Interleukin (IL)-17A activity is implicated in psoriasis. We investigated the effects of IL-17A inhibition on vascular and left ventricular (LV) function in patients with psoriasis. METHODS: A total of 150 patients with psoriasis received either an anti-IL-17A agent (secukinumab, n = 50), cyclosporine (n = 50), or methotrexate treatment (n = 50). At baseline and after 4 and 12 months of treatment, we measured (1) LV global longitudinal strain (GLS), GLS rate (GLSR), GLSR at early diastole, LV twisting, and untwisting; (2) coronary flow reserve (CFR); (3) pulse wave velocity (PWV); and (4) malondialdehyde and protein carbonyl as markers of oxidative stress. RESULTS: Compared with cyclosporine and methotrexate, anti-IL-17A treatment resulted in a greater increase in GLS at 4 and 12 months after treatment (10% and 14% with anti-IL-17A vs 2% and 2% with cyclosporine vs 4% and 4% with methotrexate, respectively), GLSR, GLSR at early diastole (45% and 41% vs 5% and 4% vs 7% and 9%, respectively), and LV twisting (32% and 28% vs 6% and 8% vs 7% and 6%, respectively) (P < 0.05). Anti-IL-17A treatment resulted in greater improvement of CFR and PWV than cyclosporine or methotrexate (P < 0.05). PWV increased after cyclosporine treatment (+11% at 4 and +14% and 12 months) (P < 0.05). Markers of oxidative stress were reduced only after anti-IL-17A treatment (P < 0.05). Changes of myocardial deformation markers and CFR after anti-IL-17A treatment correlated with a concomitant reduction of oxidative stress. CONCLUSIONS: In psoriasis, inhibition of IL-17A results in a greater improvement of vascular and myocardial function compared with cyclosporine or methotrexate treatment, indicating a beneficial effect on overall cardiovascular function.
Authors: Joel M Gelfand; Daniel B Shin; Kristina Callis Duffin; April W Armstrong; Andrew Blauvelt; Stephen K Tyring; Alan Menter; Scott Gottlieb; Benjamin N Lockshin; Eric L Simpson; Farid Kianifard; Rajendra Prasad Sarkar; Elisa Muscianisi; Jennifer Steadman; Mark A Ahlman; Martin P Playford; Aditya A Joshi; Amit K Dey; Thomas J Werner; Abass Alavi; Nehal N Mehta Journal: J Invest Dermatol Date: 2020-02-21 Impact factor: 8.551
Authors: Francesco Tona; Elena Osto; Peter L M Kerkhof; Roberta Montisci; Giulia Famoso; Giulia Lorenzoni; Laura De Michieli; Annagrazia Cecere; Irene Zanetti; Giovanni Civieri; Sabino Iliceto; Stefano Piaserico Journal: Eur J Clin Invest Date: 2021-11-25 Impact factor: 5.722